Drug intelligence / Profile preview

STX2310

Development stage: Preclinical
Lead developer: S1P Therapeutics
Modality: Small Molecules

Overview

STX2310 is a preclinical-stage drug developed by S1P Therapeutics for the treatment of acute kidney injury. It functions by targeting the sphingosine 1-phosphate (S1P) pathway, specifically by inhibiting SPNS2-dependent S1P transport. This mechanism aims to reshape S1P concentration gradients, thereby modulating S1P signaling to achieve anti-inflammatory and anti-fibrotic activities in kidney disease models, without the broad immunosuppressive effects and on-target toxicities (such as bradycardia) associated with S1P receptor modulators.

Targets

SLC superfamily (Solute carrier superfamily)

Beyond the preview

Go deeper on STX2310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STX2310.

Explore the full profile